Rightway, a healthcare navigation and pharmacy benefits platform, announced a partnership with Curai Health, an AI-powered virtual clinic, to provide Rightway's members access to Curai's virtual care offerings. Curai Health offers personalized primary care providers and urgent care services, referral management and network navigation, care programs and condition-management services, clinical workflow integration, prescription and lab ordering and white-label care services. Rightway nurses are ch

Physician, veteran and former Florida Congressman Dave Weldon is President-elect Donald Trump’s pick to lead the CDC, giving Robert F. Kennedy Jr. a key ally in his planned review of the safety of vaccines. Trump announced his decision Friday night , saying that Weldon would “prioritize Transparency, Competence, and High Standards at CDC.” He said that Americans had lost trust in the CDC and other public health agencies due to “censorship, data manipulation, and misinformation.” He echoed a broa

Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiativesGRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of i

FRANKLIN, Tenn.--( BUSINESS WIRE )--Community Health Systems, Inc. (NYSE: CYH) announced today that certain subsidiaries of the Company have entered into a definitive agreement to sell ShorePoint Health Port Charlotte in Port Charlotte, Florida, certain assets of ShorePoint Health Punta Gorda, in Punta Gorda, Florida, and certain ancillary businesses related to such facilities to subsidiaries of Adventist Health System Sunbelt Healthcare Corporation (AdventHealth) for $265 million in cash, subje

EMERYVILLE, Calif.--( BUSINESS WIRE )--NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold of favora

CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. “We are pl

President-elect Donald Trump selected Marty Makary to lead the FDA, choosing a Johns Hopkins University surgeon who has called the US government the “greatest perpetrator of misinformation during the pandemic.” Makary, the chief of islet transplant surgery at Johns Hopkins, is a health policy researcher and author who has written books about surprise billing practices at hospitals and the benefits of minimally invasive surgery. In the announcement naming Makary, Trump said he would “properly eva

The FDA approved BridgeBio’s ​​acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost against the current leader. The drug, which will be branded as Attruby, is indicated to treat transthyretin amyloid cardiomyopathy (ATTR-CM), and its wholesale acquisition cost is $18,759.12 for a 28-day supply. Over the course of a year, that equates to about $244,500. Friday’s approval comes well ahead

WASHINGTON, Nov. 22, 2024 /PRNewswire/ -- National Sleep Foundation (NSF) today announced the selection of Susan Redline, MD, MPH, as the next Editor-in-Chief for its award-winning journal Sleep Health. Dr. Redline is Peter C. Farrell Professor of Sleep Medicine at Brigham and Women's Hospital and Professor in the Department of Epidemiology at Harvard T.H. Chan School of Public Health. Dr. Redline will succeed Orfeu M. Buxton, PhD, Elizabeth Fenton Susman Professor of Biobehavioral Health and Di

Converge Bio has raised $5.5 million in seed funding led by TLV Partners. WHAT IT DOES Converge Bio is a generative AI hub for Biotech and Pharma that allows the accelerated discovery and development of drugs that use large language models (LLMs). The platform supplies a library of foundational models across all biological languages that can be amplified and adjusted for specific tasks with Converge Bio’s data enrichment pipeline. Additionally, converge Bio provides a variety of generative AI-